US FDA demystifies good laboratory practice rules for medtech
This article was originally published in SRA
The US Food and Drug Administration has issued draft guidance designed to answer commonly asked questions about the applicability of good laboratory practice (GLP) to non-clinical studies that are conducted to support medical device marketing applications and research1.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.